Sehn LH, Herrera AF, Flowers CR, et al. - Researchers examined the safety and efficacy of polatuzumab vedotin with bendamustine and obinutuzumab (pola-BG) in a single-arm cohort of patients with transplantation-ineligible relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Comparison of polatuzumab vedotin combined with bendamustine and rituximab (pola-BR) vs bendamustine and rituximab (BR) was done in a randomly assigned cohort of patients. A tolerable safety profile was reported for pola-BG and pola-BR. A CR rate of 29.6% and a median OS of 10.8 months were reported in the phase 1b/2 pola-BG cohort (n = 27) during median follow-up of 27.0 months. Findings indicate the achievement of significantly higher CR rate with polatuzumab vedotin combined with BR in addition to reduction in the risk of death by 58% compared with BR in patients with transplantation-ineligible R/R DLBCL.